One Tenacity announced the official launch of its pharmacogenomics (PGx) testing platform, a solution designed to help healthcare providers make more informed, personalized prescribing decisions based on a patient’s unique genetic profile. Testing is performed through a CAP-accredited, CLIA-registered laboratory, ensuring the highest standards of quality and regulatory compliance. The platform launch coincides with a feature episode on the WEtech Alliance podcast, where One Tenacity’s CTO and Founder, Dr. Govindaraja Atikukke, discusses the science, vision, and real-world impact of PGx testing in Canadian healthcare.
About The One Tenacity PGx Platform
What is PGx? It is the study of how genes affect a person’s response to drugs, and it is rapidly becoming a cornerstone of modern, personalized precision medicine. One Tenacity’s PGx platform bridges the gap between genetic science and clinical practice, providing actionable, evidence-based insights that inform healthcare providers when prescribing for their patients. One Tenacity PGx reports give patients the information they need to be better-informed participants in their own healthcare journeys.
Key capabilities of the One Tenacity PGx platform include:
• Comprehensive genetic panels covering metabolizer status for a wide range of commonly prescribed medications, including antidepressants, antipsychotics, pain management drugs, and cardiovascular therapies.
• Reader-friendly reporting that translates complex genomic data into clear, actionable prescribing guidance that can be reviewed with a patient’s health care provider.
• Patient-centred design that supports informed shared decision-making between providers and patients.
• Rigorous compliance framework aligned with federal and provincial health regulations, Canada’s Genetic Non-Discrimination Act, and privacy standards including PIPEDA — with all genetic data collected, used, and disclosed only with explicit written patient consent.
Why PGx – Why Now
Adverse drug reactions are among the leading causes of hospital admissions in Canada, costing the healthcare system billions of dollars annually and, more importantly, causing preventable patient harm. A significant proportion of these adverse events are attributable to genetic variability in drug metabolism — variability that One Tenacity PGx testing can identify before a prescription is ever written.
“We founded One Tenacity on a simple but powerful belief: that every patient deserves a treatment plan built around their biology, not a one-size-fits-all approach,” said One Tenacity’s Chief Technology Officer and Founder, Dr. Govindaraja Atikukke. “Our PGx platform puts that belief into practice, giving clinicians the genetic intelligence they need to guide prescribing with confidence and patients the assurance that their care is truly personalized.”
Hôtel-Dieu Grace Healthcare Partnership
One Tenacity is physically based within Hôtel-Dieu Grace Healthcare’s facilities in Windsor, Ontario, reflecting a longstanding and deeply collaborative partnership with one of the region’s leading specialty hospitals.
“Hôtel-Dieu Grace Healthcare is proud to have supported One Tenacity’s journey from the ground up — quite literally, as they have been based within our hospital for several years now. Built on over a decade of rigorous scientific research and validation, ITOS has established strong collaborative partnerships and the launch of their PGx platform reflects exactly the kind of innovation our healthcare system needs.”
— Bill Marra, President & CEO, Hôtel-Dieu Grace Healthcare
WEtech Alliance Podcast Feature
Alongside the platform launch, One Tenacity is featured in a newly released episode of WEtech Alliance’s Innovation Alchemy podcast — a platform spotlighting innovative technology companies driving economic and social impact across the Windsor-Essex region and beyond.
In the episode, Dr. Govindaraja Atikukke discusses the science behind pharmacogenomics, the barriers to PGx adoption in Canadian healthcare, and how One Tenacity’s platform is positioned to accelerate the shift toward precision medicine.
“One Tenacity is a strong example of the kind of practical innovation being built in this region,” says Adam Castle, Director of Ventures Services and Partnerships at WEtech Alliance, and host of WEtech’s Innovation Alchemy podcast. “It’s a platform that helps patients and healthcare providers work together more effectively, bringing better information and clearer insight into prescribing decisions and care plans.
“What makes it compelling is the depth behind it. This isn’t an idea that came together overnight, it’s grounded in more than a decade of pharmacogenomics research and delivered through a worldclass lab based right here in our community. Dr. Atikukke has brought a career’s worth of expertise into translating that science into something impactful for everyday Canadians.
“At WEtech, we’re proud to have played a small role in supporting the journey and to see this kind of transformative innovation taking shape locally.”
The episode is available now across all major podcast platforms, including Amazon Music, Apple Podcasts, Spotify and YouTube.
Watch or Listen to the episode: https://www.wetech-alliance.com/2026/06/04/innovation-alchemy-episode-39/
For Healthcare Professionals
One Tenacity is actively working to expand access to its PGx platform across Canada and into the United States, with initial US outreach focused on the Detroit metropolitan area. Clinicians on both sides of the border who are interested in integrating PGx testing into their practice can request a demonstration and speak with the One Tenacity team about implementation support.
For Patients
One Tenacity’s PGx testing is available for order directly through www.onetenacity.com. One Tenacity is actively working to expand patient access to PGx testing across Canada. In some instances, private health insurance may provide partial or full coverage; patients should contact their extended benefits provider to confirm eligibility. Patients are encouraged to speak with their physician, pharmacist, or specialist about whether PGx testing is right for them. All genetic data is collected, used, and disclosed only with explicit written patient consent, consistent with Canada’s Genetic Non-Discrimination Act and applicable privacy legislation. More information is available at www.onetenacity.com.
